Chronic Cough Study
Do you have chronic cough?
Currently, there is no specific treatment for people with chronic cough and most medications used to manage it may cause undesirable side effects or stop working after some time.
The CALM Studies are researching a potential new treatment option.
Critical Eligibility Criteria:
To take part in this study, you will need to meet all the following:
- Aged 18 years or older
- Have a persistent cough lasting more then 1 year
Further eligibility criteria will be assessed during pre-screening and screening.
Commitment:
Approximately 71 weeks (Approximately 20 site visits and 2 phone appointments.
Locations:
New Zealand & Australia - NSW, SA, QLD, WA
Register your Interest
The CALM Studies are looking for individuals who are between 18 and 80 years of age, and have had a chronic cough for at least 1 year that did not improve or only partially improved after medical evaluation and prescribed or over-the-counter treatments.
Contact Form
If you take part in this research study, there will be:
Reimbursement of costs
For out-of-pocket expenses, such as travel and parking.
Convenience
There are no overnight stays
Expert medical monitoring
Receive top-tier medical care and monitoring from experienced healthcare professionals.
Contribution to medical research
Help investigate a potential new treatment that could improve the lives of individuals with coeliac disease
Study Guide
01
Who can take part in this study?
-
To take part in this study, you will need to meet all the following (other criteria apply):
- Aged 18 years or older.
- Have a persistent cough lasting more than 1 year that did not improve or only partially improved following medical evaluation and prescribed or over-the-counter medications.
02
Who is unable to take part in this study?
+
Unfortunately, if any of the following apply to you, this study is not the right fit for you:
- Are a smoker, vaper or use tobacco smoke, cannabis smoke or nicotine vapor.
- Have an existing diagnosis that might affect coughing, such as chronic obstructive pulmonary disease, cystic fibrosis, or uncontrolled asthma.
Please note, additional eligibility criteria apply.
03
What does the study involve for participants?
+
If you are deemed eligible for the study, your participation is expected to last approximately 71 weeks, with approximately 20 study visits. This includes:
- A Screening period (4 weeks)
- Treatment period (55 weeks)
- Follow up period (12 weeks)
This is a double-blind study, which means neither you nor the study doctor will know if you receive the investigational medication or a placebo.
Participation in this research is voluntary, and you may withdraw from the study at any time.
04
What is the purpose of this study?
+
The CALM-2 study is testing whether BLU-5937 can safely and effectively treat refractory chronic cough, a long-lasting cough unresponsive to standard care. It compares the drug with a placebo to see if it can reduce cough frequency and improve quality of life.
05
What is Refractory Chronic Cough?
+
Refractory Chronic Cough (RCC) is a persistent cough lasting more than a year that does not improve despite thorough medical evaluation and treatment of underlying conditions (like asthma, reflux, or allergies). In other words, it’s a chronic cough with no clear cause or effective existing treatment, making it particularly challenging for patients and doctors to manage.
06
Why is this study important?
+
This study is important because refractory chronic cough (RCC) is a condition that can severely affect people’s daily lives, yet there are currently very few effective treatments available. Persistent coughing can disrupt sleep, cause physical strain, and lead to social or emotional distress. By testing BLU-5937, researchers hope to find a new, safe, and effective option to reduce cough frequency and improve quality of life for people living with RCC.
07
Where is my nearest study site?
+
Here is a list of all of the sites for this study:
Australia
- Adelaide, South Australia
- Nedlands, Western Australia
- Spearwood, Western Australia
- Brisbane, Queensland
- New Lambton, New South Wales
Selection of Site upon completion of CALM survey.
New Zealand
- Birkenhead, Auckland
- Christchurch, Canterbury
- Hamilton, Waikato
- Rotorua, Bay of Plenty
- Nelson, Nelson
- Havelock North, Hawke's Bay
- Waikanae, Wellington
Selection of Site upon completion of CALM survey.
08
What if I have other questions about the study?
+
We are here for you! Head to our Evrima Help Centre and search for answers relating to clinical trials, study information and managing your Evrilink account
This study has been approved by an independent Human Research Ethics Committee
Need help with clinical trial information?
Search our Evrima help Centre for answers related to information about our active studies, information about managing your Evrilink account, and general clinical trial knowledge!
Read our FAQs